Drugs for the treatment of pulmonary arterial hypertension
|
Status
|
Discontinued
|
| Process |
MTA
|
| Referral date |
01 April 2005 |
|
Topic area
|
- Cardiovascular
- Therapeutic procedures
|
Provisional Schedule
| Consultation on draft scope by stakeholders: |
October 2006 |
|
| Closing date for invited submissions / evidence submission: |
10 May 2007 |
| Final scope published: |
January 2007 |
| 1st appraisal committee meeting: |
03 October 2007 |
| 2nd appraisal committee meeting: |
05 February 2008 |
| 3rd appraisal committee meeting: |
03 April 2008 |
Project Team
| Assessment Group / Evidence Review Group: |
West Midlands Health Technology Assessment Collaboration |
| Communications manager: |
Kristin O'Leary |
| Executive Lead: |
Peter Littlejohns |
| Project manager: |
Jeremy Powell |
| Technical Lead: |
Helen Knight
|
Consultees
| Manufacturers / Sponsors |
Actelion Pharmaceuticals UK Ltd (bosentan) |
| |
Encysive pharmaceuticals UK Ltd (sitaxsentan) |
| |
GlaxoSmithKline (epoprostenol) |
| |
Pfizer Ltd (Sildenafil citrate) |
| |
Bayer Schering Pharma (iloprost) |
| Others |
Department of Health |
| |
London specialised commissioning Group |
| |
West Midlands Specialised Commissioning Team |
| |
Welsh Assembly Government |
| Patient / Carer Groups |
Pulmonary Hypertension Association UK |
| |
Raynaud's and Scleroderma Association |
| |
Scleroderma Society |
| Professional Groups |
British Cardiovascular Society |
| |
British Heart Foundation |
| |
British Society for Rheumatology |
| |
British Thoracic Society |
| |
National Pulmonary Hypertension Service |
| |
Royal College of Nursing |
| |
Royal College of Physicians |
Commentators
| Assessment Team |
National Coordinating Centre for Health Technology Assessment |
| |
West Midlands Health Technology Assessment Collaboration |
| Comparator Manufacturers |
None |
| General |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Medicines and Healthcare products Regulatory Agency (MHRA) |
| |
NHS Quality Improvement Scotland |
| Research Groups |
British Society for Cardiovascular Research |
|
Date
|
Update
|
|
27 May 2005
|
Topic summary published. |
|
17 October 2007
|
Timelines extended to accommodate additional analysis requested by the committee. Second committee meeting rescheduled. |
|
09 November 2007
|
Request to stakeholders seeking additional observational or registry data on the survival benefit provided by the drugs that are subject to this appraisal. |
|
28 October 2008
|
Consultees and commentators were invited to comment on a revised remit, scope and provisional matrix |
|
25 November 2008
|
Closing date for comment on draft scope, remit and matrix |
|
30 March 2009
|
The appraisal was removed from the NICE work programme |
For further information on how we develop guidance, please see our page about NICE technology appraisal guidance